Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
CERES INC. continues to rise on announcement of subsidiary acquisition of online medical consultation platform operator SQUIZ
CERES INC. <3696> continued to rise. After the close of trading on the 1st, the company announced that it had acquired 90.0% of the shares of SQUIZ (Shibuya-ku, Tokyo), which engages in the planning and operation of online medical consultation platforms, making it a subsidiary. The news has been viewed as positive.
CERES has been accumulating knowledge and a customer base in the online medical consultation field since entering the online medical consultation business in May 2022 through its online pill consultation service "Anypill." The acquisition of SQUIZ aims to strengthen its D2C online medical consultation platform business and create synergies in the vertically integrated model of its mobile services business. The acquisition price was \3.612 billion. The company noted that the impact of this transaction on its earnings is currently under review.
Source: MINKABU PRESS
Related Articles
Minkabu Individual Investor Forecasts: Mitsubishi Heavy Industries Ranks 3rd in Rising Buy Predictions
REFINVERSE Group Surges in Afternoon Trading on New Polyolefin Recycling Facility at Gamagori Plant
EIZO extends gains on planned booking of securities sale gain for fiscal year ending March 2026
Stock in Focus: FRONTIER INTERNATIONAL's Organic Subsidiaries Show Improved Profitability
Sumasapo extends gains on acquisition of municipal solution business from T&C Technologies
MCJ shares fall sharply for first time in 4 days as Bain Capital states no intention to raise TOB price
MIRAINI Holdings Surges on Planned \8.8 Billion Negative Goodwill Gain in Q1 FY03/27
KYORIN Pharma Surges on License Agreement with France's Biodol for Neuropathic Pain Drug Candidate
GNI Group surges after three-day decline on forecast of consecutive record-high sales for December 2026
Minkabu Individual Investor Sentiment: Tokio Marine Ranks 4th in Rising Sell Predictions